Next report date
Report period
H2 2023
EPS estimate
—
Revenue estimate
295.60 MCHF
5.5CHF
51.28 MCHF
497.46 MCHF
3.23 M
About YPSOMED HLDG
Sector
Industry
CEO
Simon Michel
Website
Headquarters
Burgdorf
Employees (FY)
1.98 K
Founded
2003
ISIN
CH0019396990
FIGI
BBG00NRVXZN2
Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. It operates through the following segments: Ypsomed Diabetes Care, Ypsomed Delivery Systems, and Others. The Ypsomed Diabetes Care segment is involved in the products that are sold directly to hospitals, doctors, pharmacies, and patients via Ypsomed subsidiaries and distributors. The Ypsomed Delivery Systems segment focuses on the pharmaceutical and biotech customers with injection systems and related services. The Others segment consists of Ypsotec and properties not used for operational purposes. The company was founded by Wilhelm Michel on December 29, 2003 and is headquartered in Burgdorf, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0QLQ is 339.0 CHF — it has decreased by 3.69% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange YPSOMED HOLDING AG CHF14.15 (REGD) stocks are traded under the ticker 0QLQ.
YPSOMED HOLDING AG CHF14.15 (REGD) is going to release the next earnings report on May 22, 2024. Keep track of upcoming events with our Earnings Calendar.
0QLQ stock is 4.93% volatile and has beta coefficient of 0.65. Check out the list of the most volatile stocks — is YPSOMED HOLDING AG CHF14.15 (REGD) there?
YPSOMED HOLDING AG CHF14.15 (REGD) revenue for the last quarter amounts to 253.20 M CHF despite the estimated figure of 253.90 M CHF. In the next quarter revenue is expected to reach 258.63 M CHF.
Yes, you can track YPSOMED HOLDING AG CHF14.15 (REGD) financials in yearly and quarterly reports right on TradingView.
0QLQ stock has fallen by 9.35% compared to the previous week, the month change is a 7.37% fall, over the last year YPSOMED HOLDING AG CHF14.15 (REGD) has showed a 64.18% increase.
0QLQ net income for the last quarter is 36.58 M CHF, while the quarter before that showed 35.84 M CHF of net income which accounts for 2.07% change. Track more YPSOMED HOLDING AG CHF14.15 (REGD) financial stats to get the full picture.
Today YPSOMED HOLDING AG CHF14.15 (REGD) has the market capitalization of 4.60 B, it has decreased by 4.69% over the last week.
YPSOMED HOLDING AG CHF14.15 (REGD) dividend yield was 0.68% in 2022, and payout ratio reached 34.02%. The year before the numbers were 0.37% and 32.94% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 0QLQ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade YPSOMED HOLDING AG CHF14.15 (REGD) stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has 1.98 K employees. See our rating of the largest employees — is YPSOMED HOLDING AG CHF14.15 (REGD) on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So YPSOMED HOLDING AG CHF14.15 (REGD) technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating YPSOMED HOLDING AG CHF14.15 (REGD) stock shows the buy signal. See more of YPSOMED HOLDING AG CHF14.15 (REGD) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on YPSOMED HOLDING AG CHF14.15 (REGD) future price: according to them, 0QLQ price has a max estimate of 400.00 CHF and a min estimate of 324.00 CHF. Read a more detailed YPSOMED HOLDING AG CHF14.15 (REGD) forecast: see what analysts think of YPSOMED HOLDING AG CHF14.15 (REGD) and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. YPSOMED HOLDING AG CHF14.15 (REGD) EBITDA is 134.66 M CHF, and current EBITDA margin is 23.29%. See more stats in YPSOMED HOLDING AG CHF14.15 (REGD) financial statements.